
EquitySector - HealthcareVery High Risk
Direct
NAV (19-Oct-26)
Returns (Since Inception)
Fund Size
₹3,494 Cr
Expense Ratio
0.61%
ISIN
INF769K01ED6
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+12.48%
+8.13% (Cat Avg.)
3 Years
+20.86%
+18.77% (Cat Avg.)
5 Years
+14.81%
+13.02% (Cat Avg.)
Since Inception
+20.94%
— (Cat Avg.)
| Equity | ₹3,493.48 Cr | 99.97% |
| Others | ₹0.96 Cr | 0.03% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹354.62 Cr | 10.15% |
| Divi's Laboratories Ltd | Equity | ₹342.1 Cr | 9.79% |
| Torrent Pharmaceuticals Ltd | Equity | ₹237.7 Cr | 6.80% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹196.34 Cr | 5.62% |
| Laurus Labs Ltd | Equity | ₹192.6 Cr | 5.51% |
| Dr Reddy's Laboratories Ltd | Equity | ₹169.12 Cr | 4.84% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹166.96 Cr | 4.78% |
| Aurobindo Pharma Ltd | Equity | ₹131.98 Cr | 3.78% |
| Alkem Laboratories Ltd | Equity | ₹131.36 Cr | 3.76% |
| Ipca Laboratories Ltd | Equity | ₹118.45 Cr | 3.39% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹118.43 Cr | 3.39% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹116.18 Cr | 3.32% |
| Sai Life Sciences Ltd | Equity | ₹112.79 Cr | 3.23% |
| OneSource Specialty Pharma Ltd | Equity | ₹105.27 Cr | 3.01% |
| Fortis Healthcare Ltd | Equity | ₹102.65 Cr | 2.94% |
| Dr. Lal PathLabs Ltd | Equity | ₹101.33 Cr | 2.90% |
| Gland Pharma Ltd | Equity | ₹93.92 Cr | 2.69% |
| Cipla Ltd | Equity | ₹92.01 Cr | 2.63% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹83.38 Cr | 2.39% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹81.96 Cr | 2.35% |
| Lupin Ltd | Equity | ₹79.21 Cr | 2.27% |
| Mankind Pharma Ltd | Equity | ₹78.35 Cr | 2.24% |
| Biocon Ltd | Equity | ₹70.05 Cr | 2.00% |
| Molbio Diagnostics Ltd | Equity | ₹61.89 Cr | 1.77% |
| Symbiotec Pharmalab Ltd | Equity | ₹55.81 Cr | 1.60% |
| Neogen Chemicals Ltd | Equity | ₹52.53 Cr | 1.50% |
| Anthem Biosciences Ltd | Equity | ₹32.45 Cr | 0.93% |
| Treps | Cash - Repurchase Agreement | ₹19.88 Cr | 0.57% |
| Net Receivables / (Payables) | Cash | ₹-19.16 Cr | 0.55% |
| Deepak Nitrite Ltd | Equity | ₹14 Cr | 0.40% |
| Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.25 Cr | 0.01% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.04 Cr | 0.00% |
Large Cap Stocks
34.99%
Mid Cap Stocks
42.11%
Small Cap Stocks
19.51%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹3,426.95 Cr | 98.07% |
| Basic Materials | ₹66.53 Cr | 1.90% |
Standard Deviation
This fund
16.36%
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
0.91
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better

Since July 2018
Since April 2025
ISIN INF769K01ED6 | Expense Ratio 0.61% | Exit Load 1.00% | Fund Size ₹3,494 Cr | Age 8 years 4 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,50,281 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments